Fusion Pharmaceuticals Inc. Annual Deferred Income Tax Expense (Benefit) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Fusion Pharmaceuticals Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2019 to 2023.
  • Fusion Pharmaceuticals Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$405K, a 18% increase year-over-year.
  • Fusion Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $845K.
  • Fusion Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$3.16M, a 219% decline from 2021.
  • Fusion Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$991K, a 72% decline from 2020.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $845K +$4.01M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-20
2022 -$3.16M -$2.17M -219% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-20
2021 -$991K -$415K -72% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$576K -$517K -876% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$59K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.